RECEIVED CENTRAL FAX CENTER DEC 2 2 2006

Attorney Docket No. 5515,214-US Serial No. 09/886,311 Filed: June 21, 2001 Inventors: Knudsen et al.

Via Fascimile No.: 571-273-8300

REMARKS

Claims 92, 96-99, 104-106, and 122-123 will be pending upon entry of the present amendment. Applicants have limited the claims to derivatives of exendin-4 or a fragment thereof, subject matter that the Office Action indicates to be enabled. As the present amendment should require no additional search by the Office and is believed to place the application in condition for allowance, its entry is respectfully requested.

As requested in the Office Action, a new Abstract is presented herein.

REJECTION OF THE CLAIMS UNDER 35 U.S.C. 112, FIRST PARAGRAPH

The Examiner rejected claims 92-93, 96-99, 104-106 and 122-135 (now 92, 96-99, 104-106, and 121-123) under 112, 1st paragraph.

Applicants submit that this rejection has been obviated by appropriate amendment. Page 3 of the 29 June 06 Office Action states the above-identified application is enabled for derivatives of exendin-4 or a fragment thereof. The claims are now limited to derivatives of exendin-4 or a fragment thereof. Withdrawal of this rejection is therefore respectfully requested.

Attorney Docket No. 5515.214-US Serial No. 09/886,311 Filed: June 21, 2001 Inventors: Knudson et al. Via Fascimile No.: 571-273-8300

It is believed that the claims as presented are in condition for allowance, and a determination to that effect is earnestly solicited.

Respectfully submitted,

Date: December 22, 2006

Richard W. Bork, Reg. No. 36,459

Novo Nordisk, Inc. 100 College Road West Princeton, NJ 08540 (609) 987-5800

Use the following customer number for all correspondence regarding this application

PATENT TRADEMARK OFFICS